Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02343757 · ClinicalTrials.gov registry record · NA
Alzheimer's Disease Imaging With PET/MRI - Beta-amyloid
A NA study, sponsored by University Hospitals Cleveland Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT02343757 is a NA study that was terminated before completion, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 4 participants.
The verdict
NCT02343757, a NA study, was terminated before completion, sponsored by University Hospitals Cleveland Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
The early detection of a preclinical AD or early stage of AD with amyloid imaging could improve the diagnosis and provide knowledge for better therapeutical approach by combining the best of imaging: structural MR sequences and newly FDA-approved biomarker for amyloid PET imaging, all these two techniques with their strengths in one machine. Specific Aims and Hypotheses can be summarized as follows: 1. To assess image quality and diagnostic performance of 18F-florbetapir (AMYVID) PET/MRI, including direct comparison to corresponding PET/CT images of the same patients. 2. To evaluate the incremental value of using 18F-florbetapir (AMYVID) in addition to 2-\[F-18\]-fluoro-2 deoxy-D-glucose (FDG) versus FDG alone. Does quantification of plaque burden correlate with degree of neuronal degeneration as depicted by FDG as well as with clinical severity? 3. To determine plaque burden quantitatively with 18F-florbetapir (AMYVID) in PET (form PET/CT and from PET/MR) using novel software developed specifically for these brain application; Computer-Aid Diagnosis for Dementia for amyloid imaging - CAD4D-amyloid
Interventions
- DEVICE PET/MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2013-10 |
| Est. Completion | 2016-11-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02343757
The ClinicalTrials.gov registry entry for NCT02343757 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PET/MRI is the first listed.
NCT02343757 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02343757 about?
NCT02343757 is a clinical study titled "Alzheimer's Disease Imaging With PET/MRI - Beta-amyloid". The early detection of a preclinical AD or early stage of AD with amyloid imaging could improve the diagnosis and provide knowledge for better therapeutical approach by combining the best of imaging: structural MR sequences and newly FDA-approved biomarker for amyloid PET imaging, all these two tech...
What is the current status of trial NCT02343757?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2013-10. Estimated completion is 2016-11-09.
What interventions are being tested in trial NCT02343757?
The interventions under investigation include: PET/MRI (DEVICE).
Who is sponsoring clinical trial NCT02343757?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.